The European Medicines Agency (EMA) has released today the outcome of the assessment of the first batch of applications received from medicine developers for its PRIME (PRIority MEdicines) scheme. This initiative aims to foster research and development of medicines that have the potential to address an unmet medical need.
The EMA has released the preliminary figures. Out of the 18 applications received and accessed, they have granted access to PRIME for 4 of the applications. Three of the accepted applications are from Small and Medium size Enterprises. They belong to oncology, immunology-rheumatology-transplantation, neurology, and hematology-hemostaseology therapeutic groups.